nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—DRD5—eyelid—skin cancer	0.0418	0.14	CbGeAlD
Loxapine—Phototoxicity—Imiquimod—skin cancer	0.0289	0.0654	CcSEcCtD
Loxapine—CHRM3—muscle of abdomen—skin cancer	0.0179	0.06	CbGeAlD
Loxapine—HRH1—nose—skin cancer	0.0139	0.0464	CbGeAlD
Loxapine—Amenorrhoea—Vismodegib—skin cancer	0.012	0.0271	CcSEcCtD
Loxapine—CHRM5—skin epidermis—skin cancer	0.0117	0.0393	CbGeAlD
Loxapine—DRD1—nerve—skin cancer	0.00852	0.0285	CbGeAlD
Loxapine—HTR3A—nerve—skin cancer	0.00822	0.0275	CbGeAlD
Loxapine—HTR5A—head—skin cancer	0.00811	0.0271	CbGeAlD
Loxapine—SLC6A3—nerve—skin cancer	0.00684	0.0229	CbGeAlD
Loxapine—Slurred speech—Fluorouracil—skin cancer	0.00684	0.0155	CcSEcCtD
Loxapine—Weight decreased—Vismodegib—skin cancer	0.00596	0.0135	CcSEcCtD
Loxapine—SLC6A2—nerve—skin cancer	0.00552	0.0185	CbGeAlD
Loxapine—HTR2A—hindlimb—skin cancer	0.00546	0.0183	CbGeAlD
Loxapine—HTR1B—blood vessel—skin cancer	0.00542	0.0181	CbGeAlD
Loxapine—Photosensitivity—Vemurafenib—skin cancer	0.00537	0.0122	CcSEcCtD
Loxapine—HTR7—nerve—skin cancer	0.00532	0.0178	CbGeAlD
Loxapine—HTR1D—blood vessel—skin cancer	0.00525	0.0175	CbGeAlD
Loxapine—DRD2—nerve—skin cancer	0.00503	0.0168	CbGeAlD
Loxapine—Chest tightness—Docetaxel—skin cancer	0.00471	0.0107	CcSEcCtD
Loxapine—HTR2A—appendage—skin cancer	0.00468	0.0157	CbGeAlD
Loxapine—Alopecia—Vismodegib—skin cancer	0.00466	0.0106	CcSEcCtD
Loxapine—HTR7—endothelium—skin cancer	0.00453	0.0152	CbGeAlD
Loxapine—Dysgeusia—Vismodegib—skin cancer	0.0045	0.0102	CcSEcCtD
Loxapine—Muscle spasms—Vismodegib—skin cancer	0.00442	0.01	CcSEcCtD
Loxapine—Nasal congestion—Imiquimod—skin cancer	0.00441	0.01	CcSEcCtD
Loxapine—Extrapyramidal disorder—Temozolomide—skin cancer	0.00441	0.00999	CcSEcCtD
Loxapine—HTR7—blood vessel—skin cancer	0.00418	0.014	CbGeAlD
Loxapine—Cerebrovascular accident—Imiquimod—skin cancer	0.0041	0.00929	CcSEcCtD
Loxapine—Menstruation irregular—Docetaxel—skin cancer	0.00399	0.00903	CcSEcCtD
Loxapine—Liver injury—Temozolomide—skin cancer	0.00394	0.00894	CcSEcCtD
Loxapine—CHRM5—epithelium—skin cancer	0.00382	0.0128	CbGeAlD
Loxapine—Urinary retention—Imiquimod—skin cancer	0.00382	0.00866	CcSEcCtD
Loxapine—Wheezing—Bleomycin—skin cancer	0.00382	0.00866	CcSEcCtD
Loxapine—HRH2—skin of body—skin cancer	0.00381	0.0127	CbGeAlD
Loxapine—Amenorrhoea—Temozolomide—skin cancer	0.00378	0.00856	CcSEcCtD
Loxapine—Photosensitivity reaction—Vemurafenib—skin cancer	0.00372	0.00843	CcSEcCtD
Loxapine—Numbness—Fluorouracil—skin cancer	0.00369	0.00836	CcSEcCtD
Loxapine—Weight decreased—Vemurafenib—skin cancer	0.00368	0.00835	CcSEcCtD
Loxapine—Nervous system disorder—Vismodegib—skin cancer	0.00368	0.00833	CcSEcCtD
Loxapine—CHRM5—skin of body—skin cancer	0.00363	0.0122	CbGeAlD
Loxapine—Sensory loss—Fluorouracil—skin cancer	0.00353	0.008	CcSEcCtD
Loxapine—HTR1E—head—skin cancer	0.00346	0.0116	CbGeAlD
Loxapine—Gait disturbance—Temozolomide—skin cancer	0.0034	0.0077	CcSEcCtD
Loxapine—HTR2A—nerve—skin cancer	0.00332	0.0111	CbGeAlD
Loxapine—DRD5—lymphoid tissue—skin cancer	0.00328	0.011	CbGeAlD
Loxapine—Gastrointestinal disorder—Vismodegib—skin cancer	0.00324	0.00734	CcSEcCtD
Loxapine—Fatigue—Vismodegib—skin cancer	0.00323	0.00733	CcSEcCtD
Loxapine—Dysarthria—Fluorouracil—skin cancer	0.00323	0.00732	CcSEcCtD
Loxapine—Constipation—Vismodegib—skin cancer	0.00321	0.00727	CcSEcCtD
Loxapine—Photosensitivity reaction—Imiquimod—skin cancer	0.00317	0.00719	CcSEcCtD
Loxapine—DRD5—female reproductive system—skin cancer	0.00316	0.0106	CbGeAlD
Loxapine—Dry eye—Temozolomide—skin cancer	0.00306	0.00695	CcSEcCtD
Loxapine—CHRM4—head—skin cancer	0.00303	0.0102	CbGeAlD
Loxapine—HTR7—neck—skin cancer	0.00299	0.01	CbGeAlD
Loxapine—Angiopathy—Vemurafenib—skin cancer	0.00296	0.0067	CcSEcCtD
Loxapine—Mediastinal disorder—Vemurafenib—skin cancer	0.00294	0.00666	CcSEcCtD
Loxapine—Cerebrovascular accident—Bleomycin—skin cancer	0.00291	0.0066	CcSEcCtD
Loxapine—Alopecia—Vemurafenib—skin cancer	0.00288	0.00653	CcSEcCtD
Loxapine—HTR2A—endothelium—skin cancer	0.00283	0.00945	CbGeAlD
Loxapine—DRD3—head—skin cancer	0.00282	0.00944	CbGeAlD
Loxapine—Dysgeusia—Vemurafenib—skin cancer	0.00278	0.0063	CcSEcCtD
Loxapine—ADRA2C—nipple—skin cancer	0.00278	0.00929	CbGeAlD
Loxapine—HTR6—head—skin cancer	0.00272	0.00908	CbGeAlD
Loxapine—Asthenia—Vismodegib—skin cancer	0.00269	0.0061	CcSEcCtD
Loxapine—HTR1D—connective tissue—skin cancer	0.00269	0.009	CbGeAlD
Loxapine—Pruritus—Vismodegib—skin cancer	0.00265	0.00601	CcSEcCtD
Loxapine—Nasal congestion—Temozolomide—skin cancer	0.00264	0.00599	CcSEcCtD
Loxapine—DRD5—head—skin cancer	0.00264	0.00884	CbGeAlD
Loxapine—ADRB1—connective tissue—skin cancer	0.00261	0.00874	CbGeAlD
Loxapine—HTR2A—blood vessel—skin cancer	0.00261	0.00872	CbGeAlD
Loxapine—Photosensitivity—Fluorouracil—skin cancer	0.00253	0.00573	CcSEcCtD
Loxapine—Angiopathy—Imiquimod—skin cancer	0.00252	0.00572	CcSEcCtD
Loxapine—Amenorrhoea—Docetaxel—skin cancer	0.00251	0.00569	CcSEcCtD
Loxapine—Mediastinal disorder—Imiquimod—skin cancer	0.00251	0.00568	CcSEcCtD
Loxapine—Chest discomfort—Docetaxel—skin cancer	0.00249	0.00565	CcSEcCtD
Loxapine—HRH2—head—skin cancer	0.00248	0.00831	CbGeAlD
Loxapine—Cough—Vemurafenib—skin cancer	0.00248	0.00561	CcSEcCtD
Loxapine—Alopecia—Imiquimod—skin cancer	0.00246	0.00557	CcSEcCtD
Loxapine—Bronchospasm—Bleomycin—skin cancer	0.00243	0.0055	CcSEcCtD
Loxapine—Vomiting—Vismodegib—skin cancer	0.00238	0.0054	CcSEcCtD
Loxapine—CHRM5—head—skin cancer	0.00237	0.00793	CbGeAlD
Loxapine—Rash—Vismodegib—skin cancer	0.00236	0.00536	CcSEcCtD
Loxapine—Dermatitis—Vismodegib—skin cancer	0.00236	0.00535	CcSEcCtD
Loxapine—Dysphagia—Dactinomycin—skin cancer	0.0023	0.00522	CcSEcCtD
Loxapine—Nervous system disorder—Vemurafenib—skin cancer	0.00227	0.00515	CcSEcCtD
Loxapine—HRH1—nipple—skin cancer	0.00226	0.00755	CbGeAlD
Loxapine—Weight decreased—Bleomycin—skin cancer	0.00223	0.00506	CcSEcCtD
Loxapine—Nausea—Vismodegib—skin cancer	0.00223	0.00505	CcSEcCtD
Loxapine—Agitation—Imiquimod—skin cancer	0.00222	0.00504	CcSEcCtD
Loxapine—ADRA2A—nipple—skin cancer	0.00222	0.00741	CbGeAlD
Loxapine—Hepatocellular injury—Docetaxel—skin cancer	0.00221	0.005	CcSEcCtD
Loxapine—Syncope—Imiquimod—skin cancer	0.00217	0.00492	CcSEcCtD
Loxapine—ADRA1B—head—skin cancer	0.00217	0.00725	CbGeAlD
Loxapine—Hypotension—Vemurafenib—skin cancer	0.00216	0.00491	CcSEcCtD
Loxapine—HTR7—connective tissue—skin cancer	0.00214	0.00717	CbGeAlD
Loxapine—Loss of consciousness—Imiquimod—skin cancer	0.00213	0.00482	CcSEcCtD
Loxapine—Cough—Imiquimod—skin cancer	0.00211	0.00479	CcSEcCtD
Loxapine—Convulsion—Imiquimod—skin cancer	0.0021	0.00475	CcSEcCtD
Loxapine—Hypertension—Imiquimod—skin cancer	0.00209	0.00474	CcSEcCtD
Loxapine—Dysphagia—Temozolomide—skin cancer	0.00208	0.00472	CcSEcCtD
Loxapine—Chest pain—Imiquimod—skin cancer	0.00206	0.00467	CcSEcCtD
Loxapine—HTR7—epithelium—skin cancer	0.00203	0.0068	CbGeAlD
Loxapine—DRD1—head—skin cancer	0.00202	0.00676	CbGeAlD
Loxapine—Dry mouth—Imiquimod—skin cancer	0.00202	0.00457	CcSEcCtD
Loxapine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.002	0.00453	CcSEcCtD
Loxapine—Fatigue—Vemurafenib—skin cancer	0.002	0.00453	CcSEcCtD
Loxapine—Constipation—Vemurafenib—skin cancer	0.00198	0.00449	CcSEcCtD
Loxapine—Oedema—Imiquimod—skin cancer	0.00198	0.00448	CcSEcCtD
Loxapine—Lightheadedness—Docetaxel—skin cancer	0.00197	0.00447	CcSEcCtD
Loxapine—Hypoaesthesia—Bleomycin—skin cancer	0.00197	0.00445	CcSEcCtD
Loxapine—ADRA1A—epithelium—skin cancer	0.00196	0.00656	CbGeAlD
Loxapine—HTR1B—female reproductive system—skin cancer	0.00196	0.00655	CbGeAlD
Loxapine—HTR3A—head—skin cancer	0.00195	0.00653	CbGeAlD
Loxapine—Shock—Imiquimod—skin cancer	0.00194	0.0044	CcSEcCtD
Loxapine—Nervous system disorder—Imiquimod—skin cancer	0.00194	0.00439	CcSEcCtD
Loxapine—Tachycardia—Imiquimod—skin cancer	0.00193	0.00437	CcSEcCtD
Loxapine—Dysphagia—Fluorouracil—skin cancer	0.00192	0.00435	CcSEcCtD
Loxapine—Agranulocytosis—Dactinomycin—skin cancer	0.00191	0.00434	CcSEcCtD
Loxapine—Photosensitivity reaction—Temozolomide—skin cancer	0.0019	0.00431	CcSEcCtD
Loxapine—HTR1D—female reproductive system—skin cancer	0.0019	0.00635	CbGeAlD
Loxapine—Weight increased—Temozolomide—skin cancer	0.00189	0.00429	CcSEcCtD
Loxapine—Weight decreased—Temozolomide—skin cancer	0.00188	0.00427	CcSEcCtD
Loxapine—HTR2C—female reproductive system—skin cancer	0.00188	0.00628	CbGeAlD
Loxapine—HTR2A—neck—skin cancer	0.00186	0.00624	CbGeAlD
Loxapine—ADRB1—female reproductive system—skin cancer	0.00184	0.00617	CbGeAlD
Loxapine—Hepatitis—Dactinomycin—skin cancer	0.00184	0.00417	CcSEcCtD
Loxapine—Insomnia—Imiquimod—skin cancer	0.00179	0.00405	CcSEcCtD
Loxapine—SLC6A4—female reproductive system—skin cancer	0.00178	0.00596	CbGeAlD
Loxapine—CHRM1—female reproductive system—skin cancer	0.00177	0.00593	CbGeAlD
Loxapine—Paraesthesia—Imiquimod—skin cancer	0.00177	0.00402	CcSEcCtD
Loxapine—Dyspnoea—Imiquimod—skin cancer	0.00176	0.00399	CcSEcCtD
Loxapine—Somnolence—Imiquimod—skin cancer	0.00176	0.00398	CcSEcCtD
Loxapine—Photosensitivity reaction—Fluorouracil—skin cancer	0.00175	0.00397	CcSEcCtD
Loxapine—Alopecia—Bleomycin—skin cancer	0.00175	0.00396	CcSEcCtD
Loxapine—HRH2—lymph node—skin cancer	0.00174	0.00582	CbGeAlD
Loxapine—Hypersensitivity—Vemurafenib—skin cancer	0.00171	0.00387	CcSEcCtD
Loxapine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00171	0.00386	CcSEcCtD
Loxapine—Fatigue—Imiquimod—skin cancer	0.0017	0.00386	CcSEcCtD
Loxapine—Hepatitis—Temozolomide—skin cancer	0.00167	0.00378	CcSEcCtD
Loxapine—Asthenia—Vemurafenib—skin cancer	0.00166	0.00377	CcSEcCtD
Loxapine—Hypoaesthesia—Temozolomide—skin cancer	0.00166	0.00376	CcSEcCtD
Loxapine—Pruritus—Vemurafenib—skin cancer	0.00164	0.00371	CcSEcCtD
Loxapine—HTR1B—head—skin cancer	0.00164	0.00548	CbGeAlD
Loxapine—CHRM2—head—skin cancer	0.00163	0.00545	CbGeAlD
Loxapine—Alopecia—Dactinomycin—skin cancer	0.00163	0.00369	CcSEcCtD
Loxapine—Feeling abnormal—Imiquimod—skin cancer	0.00163	0.00369	CcSEcCtD
Loxapine—SLC6A3—head—skin cancer	0.00162	0.00543	CbGeAlD
Loxapine—ADRA2C—mammalian vulva—skin cancer	0.00162	0.00543	CbGeAlD
Loxapine—HRH1—connective tissue—skin cancer	0.0016	0.00535	CbGeAlD
Loxapine—Agranulocytosis—Fluorouracil—skin cancer	0.0016	0.00362	CcSEcCtD
Loxapine—CHRM3—female reproductive system—skin cancer	0.00159	0.00531	CbGeAlD
Loxapine—HTR1D—head—skin cancer	0.00158	0.0053	CbGeAlD
Loxapine—ADRA2A—connective tissue—skin cancer	0.00157	0.00526	CbGeAlD
Loxapine—HTR2C—head—skin cancer	0.00157	0.00525	CbGeAlD
Loxapine—SLC6A2—female reproductive system—skin cancer	0.00157	0.00524	CbGeAlD
Loxapine—ADRB1—head—skin cancer	0.00154	0.00515	CbGeAlD
Loxapine—Leukopenia—Bleomycin—skin cancer	0.00154	0.00349	CcSEcCtD
Loxapine—Dizziness—Vemurafenib—skin cancer	0.00153	0.00347	CcSEcCtD
Loxapine—Hypoaesthesia—Fluorouracil—skin cancer	0.00153	0.00346	CcSEcCtD
Loxapine—HRH1—epithelium—skin cancer	0.00152	0.00508	CbGeAlD
Loxapine—Angiopathy—Temozolomide—skin cancer	0.00151	0.00343	CcSEcCtD
Loxapine—ADRA1A—lymphoid tissue—skin cancer	0.00151	0.00506	CbGeAlD
Loxapine—HTR7—female reproductive system—skin cancer	0.00151	0.00505	CbGeAlD
Loxapine—Mediastinal disorder—Temozolomide—skin cancer	0.0015	0.0034	CcSEcCtD
Loxapine—Cough—Bleomycin—skin cancer	0.0015	0.0034	CcSEcCtD
Loxapine—SLC6A4—head—skin cancer	0.00149	0.00498	CbGeAlD
Loxapine—CHRM1—head—skin cancer	0.00148	0.00496	CbGeAlD
Loxapine—Vomiting—Vemurafenib—skin cancer	0.00147	0.00334	CcSEcCtD
Loxapine—Alopecia—Temozolomide—skin cancer	0.00147	0.00334	CcSEcCtD
Loxapine—Chest pain—Bleomycin—skin cancer	0.00146	0.00332	CcSEcCtD
Loxapine—Orthostatic hypotension—Docetaxel—skin cancer	0.00146	0.00332	CcSEcCtD
Loxapine—Rash—Vemurafenib—skin cancer	0.00146	0.00331	CcSEcCtD
Loxapine—Dermatitis—Vemurafenib—skin cancer	0.00146	0.00331	CcSEcCtD
Loxapine—Hypersensitivity—Imiquimod—skin cancer	0.00146	0.0033	CcSEcCtD
Loxapine—Headache—Vemurafenib—skin cancer	0.00145	0.00329	CcSEcCtD
Loxapine—Leukopenia—Dactinomycin—skin cancer	0.00144	0.00325	CcSEcCtD
Loxapine—Dysgeusia—Temozolomide—skin cancer	0.00142	0.00322	CcSEcCtD
Loxapine—Asthenia—Imiquimod—skin cancer	0.00142	0.00321	CcSEcCtD
Loxapine—Confusional state—Bleomycin—skin cancer	0.00141	0.00321	CcSEcCtD
Loxapine—Oedema—Bleomycin—skin cancer	0.0014	0.00318	CcSEcCtD
Loxapine—Pruritus—Imiquimod—skin cancer	0.0014	0.00317	CcSEcCtD
Loxapine—Dysphagia—Docetaxel—skin cancer	0.00138	0.00314	CcSEcCtD
Loxapine—Nausea—Vemurafenib—skin cancer	0.00138	0.00312	CcSEcCtD
Loxapine—Thrombocytopenia—Bleomycin—skin cancer	0.00137	0.00311	CcSEcCtD
Loxapine—Vision blurred—Temozolomide—skin cancer	0.00137	0.0031	CcSEcCtD
Loxapine—Bronchospasm—Docetaxel—skin cancer	0.00136	0.00309	CcSEcCtD
Loxapine—Tremor—Temozolomide—skin cancer	0.00136	0.00308	CcSEcCtD
Loxapine—Alopecia—Fluorouracil—skin cancer	0.00136	0.00307	CcSEcCtD
Loxapine—HTR2A—connective tissue—skin cancer	0.00134	0.00447	CbGeAlD
Loxapine—Agitation—Temozolomide—skin cancer	0.00133	0.00302	CcSEcCtD
Loxapine—CHRM3—head—skin cancer	0.00133	0.00444	CbGeAlD
Loxapine—HTR1A—head—skin cancer	0.00132	0.00442	CbGeAlD
Loxapine—HRH1—mammalian vulva—skin cancer	0.00132	0.00441	CbGeAlD
Loxapine—Hypotension—Bleomycin—skin cancer	0.00131	0.00297	CcSEcCtD
Loxapine—SLC6A2—head—skin cancer	0.00131	0.00438	CbGeAlD
Loxapine—Oedema—Dactinomycin—skin cancer	0.00131	0.00297	CcSEcCtD
Loxapine—Dizziness—Imiquimod—skin cancer	0.00131	0.00296	CcSEcCtD
Loxapine—Leukopenia—Temozolomide—skin cancer	0.0013	0.00294	CcSEcCtD
Loxapine—ADRA2A—mammalian vulva—skin cancer	0.00129	0.00433	CbGeAlD
Loxapine—Thrombocytopenia—Dactinomycin—skin cancer	0.00128	0.0029	CcSEcCtD
Loxapine—HTR2A—epithelium—skin cancer	0.00127	0.00424	CbGeAlD
Loxapine—Cough—Temozolomide—skin cancer	0.00127	0.00287	CcSEcCtD
Loxapine—HTR7—head—skin cancer	0.00126	0.00422	CbGeAlD
Loxapine—Paraesthesia—Bleomycin—skin cancer	0.00126	0.00286	CcSEcCtD
Loxapine—Weight increased—Docetaxel—skin cancer	0.00126	0.00286	CcSEcCtD
Loxapine—Vision blurred—Fluorouracil—skin cancer	0.00126	0.00285	CcSEcCtD
Loxapine—Convulsion—Temozolomide—skin cancer	0.00126	0.00285	CcSEcCtD
Loxapine—Vomiting—Imiquimod—skin cancer	0.00126	0.00285	CcSEcCtD
Loxapine—Weight decreased—Docetaxel—skin cancer	0.00125	0.00284	CcSEcCtD
Loxapine—Hypertension—Temozolomide—skin cancer	0.00125	0.00284	CcSEcCtD
Loxapine—Dyspnoea—Bleomycin—skin cancer	0.00125	0.00284	CcSEcCtD
Loxapine—Rash—Imiquimod—skin cancer	0.00125	0.00282	CcSEcCtD
Loxapine—Dermatitis—Imiquimod—skin cancer	0.00124	0.00282	CcSEcCtD
Loxapine—Headache—Imiquimod—skin cancer	0.00124	0.0028	CcSEcCtD
Loxapine—ADRA1A—head—skin cancer	0.00122	0.00407	CbGeAlD
Loxapine—Renal failure—Docetaxel—skin cancer	0.00121	0.00275	CcSEcCtD
Loxapine—Dry mouth—Temozolomide—skin cancer	0.00121	0.00274	CcSEcCtD
Loxapine—Jaundice—Docetaxel—skin cancer	0.0012	0.00273	CcSEcCtD
Loxapine—Leukopenia—Fluorouracil—skin cancer	0.0012	0.00271	CcSEcCtD
Loxapine—Confusional state—Temozolomide—skin cancer	0.00119	0.00271	CcSEcCtD
Loxapine—DRD2—head—skin cancer	0.00119	0.00399	CbGeAlD
Loxapine—Oedema—Temozolomide—skin cancer	0.00118	0.00268	CcSEcCtD
Loxapine—Nausea—Imiquimod—skin cancer	0.00117	0.00266	CcSEcCtD
Loxapine—Nervous system disorder—Temozolomide—skin cancer	0.00116	0.00263	CcSEcCtD
Loxapine—ADRA2C—head—skin cancer	0.00116	0.00388	CbGeAlD
Loxapine—Thrombocytopenia—Temozolomide—skin cancer	0.00116	0.00263	CcSEcCtD
Loxapine—Convulsion—Fluorouracil—skin cancer	0.00116	0.00262	CcSEcCtD
Loxapine—Feeling abnormal—Bleomycin—skin cancer	0.00116	0.00262	CcSEcCtD
Loxapine—Agranulocytosis—Docetaxel—skin cancer	0.00115	0.00261	CcSEcCtD
Loxapine—Chest pain—Fluorouracil—skin cancer	0.00114	0.00258	CcSEcCtD
Loxapine—Fatigue—Dactinomycin—skin cancer	0.00113	0.00256	CcSEcCtD
Loxapine—HRH1—female reproductive system—skin cancer	0.00113	0.00377	CbGeAlD
Loxapine—ADRA2A—female reproductive system—skin cancer	0.00111	0.00371	CbGeAlD
Loxapine—Hepatitis—Docetaxel—skin cancer	0.00111	0.00251	CcSEcCtD
Loxapine—Hypoaesthesia—Docetaxel—skin cancer	0.0011	0.0025	CcSEcCtD
Loxapine—Confusional state—Fluorouracil—skin cancer	0.0011	0.00249	CcSEcCtD
Loxapine—Oedema—Fluorouracil—skin cancer	0.00109	0.00247	CcSEcCtD
Loxapine—Feeling abnormal—Dactinomycin—skin cancer	0.00108	0.00244	CcSEcCtD
Loxapine—Insomnia—Temozolomide—skin cancer	0.00107	0.00243	CcSEcCtD
Loxapine—Nervous system disorder—Fluorouracil—skin cancer	0.00107	0.00242	CcSEcCtD
Loxapine—Thrombocytopenia—Fluorouracil—skin cancer	0.00107	0.00242	CcSEcCtD
Loxapine—Tachycardia—Fluorouracil—skin cancer	0.00106	0.00241	CcSEcCtD
Loxapine—Paraesthesia—Temozolomide—skin cancer	0.00106	0.00241	CcSEcCtD
Loxapine—Dyspnoea—Temozolomide—skin cancer	0.00106	0.00239	CcSEcCtD
Loxapine—Somnolence—Temozolomide—skin cancer	0.00105	0.00238	CcSEcCtD
Loxapine—Hypersensitivity—Bleomycin—skin cancer	0.00103	0.00234	CcSEcCtD
Loxapine—Gastrointestinal disorder—Temozolomide—skin cancer	0.00102	0.00232	CcSEcCtD
Loxapine—Fatigue—Temozolomide—skin cancer	0.00102	0.00231	CcSEcCtD
Loxapine—Hypotension—Fluorouracil—skin cancer	0.00102	0.00231	CcSEcCtD
Loxapine—Constipation—Temozolomide—skin cancer	0.00101	0.00229	CcSEcCtD
Loxapine—Asthenia—Bleomycin—skin cancer	0.00101	0.00228	CcSEcCtD
Loxapine—Angiopathy—Docetaxel—skin cancer	0.00101	0.00228	CcSEcCtD
Loxapine—Mediastinal disorder—Docetaxel—skin cancer	0.000999	0.00226	CcSEcCtD
Loxapine—Pruritus—Bleomycin—skin cancer	0.000993	0.00225	CcSEcCtD
Loxapine—Insomnia—Fluorouracil—skin cancer	0.000986	0.00224	CcSEcCtD
Loxapine—Paraesthesia—Fluorouracil—skin cancer	0.000979	0.00222	CcSEcCtD
Loxapine—Alopecia—Docetaxel—skin cancer	0.000979	0.00222	CcSEcCtD
Loxapine—Feeling abnormal—Temozolomide—skin cancer	0.000975	0.00221	CcSEcCtD
Loxapine—Dyspnoea—Fluorouracil—skin cancer	0.000972	0.0022	CcSEcCtD
Loxapine—Somnolence—Fluorouracil—skin cancer	0.00097	0.0022	CcSEcCtD
Loxapine—Hypersensitivity—Dactinomycin—skin cancer	0.000964	0.00219	CcSEcCtD
Loxapine—Dysgeusia—Docetaxel—skin cancer	0.000945	0.00214	CcSEcCtD
Loxapine—HRH1—head—skin cancer	0.000942	0.00315	CbGeAlD
Loxapine—HTR2A—female reproductive system—skin cancer	0.000942	0.00315	CbGeAlD
Loxapine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000942	0.00213	CcSEcCtD
Loxapine—Asthenia—Dactinomycin—skin cancer	0.000939	0.00213	CcSEcCtD
Loxapine—Muscle spasms—Docetaxel—skin cancer	0.000927	0.0021	CcSEcCtD
Loxapine—ADRA2A—head—skin cancer	0.000926	0.0031	CbGeAlD
Loxapine—SLC6A2—lymph node—skin cancer	0.000917	0.00307	CbGeAlD
Loxapine—Feeling abnormal—Fluorouracil—skin cancer	0.000899	0.00204	CcSEcCtD
Loxapine—Vomiting—Bleomycin—skin cancer	0.000892	0.00202	CcSEcCtD
Loxapine—Rash—Bleomycin—skin cancer	0.000885	0.00201	CcSEcCtD
Loxapine—Dermatitis—Bleomycin—skin cancer	0.000884	0.002	CcSEcCtD
Loxapine—Hypersensitivity—Temozolomide—skin cancer	0.000872	0.00198	CcSEcCtD
Loxapine—Syncope—Docetaxel—skin cancer	0.000865	0.00196	CcSEcCtD
Loxapine—Leukopenia—Docetaxel—skin cancer	0.000863	0.00196	CcSEcCtD
Loxapine—Asthenia—Temozolomide—skin cancer	0.000849	0.00192	CcSEcCtD
Loxapine—Loss of consciousness—Docetaxel—skin cancer	0.000848	0.00192	CcSEcCtD
Loxapine—Cough—Docetaxel—skin cancer	0.000842	0.00191	CcSEcCtD
Loxapine—Pruritus—Temozolomide—skin cancer	0.000837	0.0019	CcSEcCtD
Loxapine—Convulsion—Docetaxel—skin cancer	0.000836	0.00189	CcSEcCtD
Loxapine—Nausea—Bleomycin—skin cancer	0.000834	0.00189	CcSEcCtD
Loxapine—Hypertension—Docetaxel—skin cancer	0.000833	0.00189	CcSEcCtD
Loxapine—Vomiting—Dactinomycin—skin cancer	0.000832	0.00189	CcSEcCtD
Loxapine—Rash—Dactinomycin—skin cancer	0.000825	0.00187	CcSEcCtD
Loxapine—Chest pain—Docetaxel—skin cancer	0.000821	0.00186	CcSEcCtD
Loxapine—ADRA2C—lymph node—skin cancer	0.000812	0.00272	CbGeAlD
Loxapine—Hypersensitivity—Fluorouracil—skin cancer	0.000804	0.00182	CcSEcCtD
Loxapine—Dry mouth—Docetaxel—skin cancer	0.000803	0.00182	CcSEcCtD
Loxapine—Confusional state—Docetaxel—skin cancer	0.000794	0.0018	CcSEcCtD
Loxapine—Oedema—Docetaxel—skin cancer	0.000787	0.00178	CcSEcCtD
Loxapine—HTR2A—head—skin cancer	0.000787	0.00263	CbGeAlD
Loxapine—Dizziness—Temozolomide—skin cancer	0.000783	0.00177	CcSEcCtD
Loxapine—Nausea—Dactinomycin—skin cancer	0.000777	0.00176	CcSEcCtD
Loxapine—Shock—Docetaxel—skin cancer	0.000774	0.00176	CcSEcCtD
Loxapine—Nervous system disorder—Docetaxel—skin cancer	0.000772	0.00175	CcSEcCtD
Loxapine—Pruritus—Fluorouracil—skin cancer	0.000772	0.00175	CcSEcCtD
Loxapine—Thrombocytopenia—Docetaxel—skin cancer	0.000771	0.00175	CcSEcCtD
Loxapine—Tachycardia—Docetaxel—skin cancer	0.000768	0.00174	CcSEcCtD
Loxapine—Vomiting—Temozolomide—skin cancer	0.000753	0.00171	CcSEcCtD
Loxapine—Rash—Temozolomide—skin cancer	0.000746	0.00169	CcSEcCtD
Loxapine—Dermatitis—Temozolomide—skin cancer	0.000746	0.00169	CcSEcCtD
Loxapine—Headache—Temozolomide—skin cancer	0.000742	0.00168	CcSEcCtD
Loxapine—Hypotension—Docetaxel—skin cancer	0.000736	0.00167	CcSEcCtD
Loxapine—Dizziness—Fluorouracil—skin cancer	0.000721	0.00163	CcSEcCtD
Loxapine—Insomnia—Docetaxel—skin cancer	0.000712	0.00161	CcSEcCtD
Loxapine—Paraesthesia—Docetaxel—skin cancer	0.000707	0.0016	CcSEcCtD
Loxapine—Nausea—Temozolomide—skin cancer	0.000703	0.00159	CcSEcCtD
Loxapine—Dyspnoea—Docetaxel—skin cancer	0.000702	0.00159	CcSEcCtD
Loxapine—Somnolence—Docetaxel—skin cancer	0.0007	0.00159	CcSEcCtD
Loxapine—Vomiting—Fluorouracil—skin cancer	0.000693	0.00157	CcSEcCtD
Loxapine—Rash—Fluorouracil—skin cancer	0.000688	0.00156	CcSEcCtD
Loxapine—Dermatitis—Fluorouracil—skin cancer	0.000687	0.00156	CcSEcCtD
Loxapine—Headache—Fluorouracil—skin cancer	0.000683	0.00155	CcSEcCtD
Loxapine—Gastrointestinal disorder—Docetaxel—skin cancer	0.00068	0.00154	CcSEcCtD
Loxapine—Fatigue—Docetaxel—skin cancer	0.000679	0.00154	CcSEcCtD
Loxapine—Constipation—Docetaxel—skin cancer	0.000673	0.00153	CcSEcCtD
Loxapine—HRH1—lymph node—skin cancer	0.00066	0.00221	CbGeAlD
Loxapine—Feeling abnormal—Docetaxel—skin cancer	0.000649	0.00147	CcSEcCtD
Loxapine—ADRA2A—lymph node—skin cancer	0.000648	0.00217	CbGeAlD
Loxapine—Nausea—Fluorouracil—skin cancer	0.000648	0.00147	CcSEcCtD
Loxapine—Hypersensitivity—Docetaxel—skin cancer	0.00058	0.00131	CcSEcCtD
Loxapine—Asthenia—Docetaxel—skin cancer	0.000565	0.00128	CcSEcCtD
Loxapine—Pruritus—Docetaxel—skin cancer	0.000557	0.00126	CcSEcCtD
Loxapine—Dizziness—Docetaxel—skin cancer	0.000521	0.00118	CcSEcCtD
Loxapine—Vomiting—Docetaxel—skin cancer	0.000501	0.00113	CcSEcCtD
Loxapine—Rash—Docetaxel—skin cancer	0.000496	0.00112	CcSEcCtD
Loxapine—Dermatitis—Docetaxel—skin cancer	0.000496	0.00112	CcSEcCtD
Loxapine—Headache—Docetaxel—skin cancer	0.000493	0.00112	CcSEcCtD
Loxapine—Nausea—Docetaxel—skin cancer	0.000468	0.00106	CcSEcCtD
Loxapine—DRD1—Signaling by GPCR—NRAS—skin cancer	3.67e-05	0.000141	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—KRAS—skin cancer	3.67e-05	0.000141	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—KRAS—skin cancer	3.67e-05	0.000141	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—KRAS—skin cancer	3.65e-05	0.00014	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—KRAS—skin cancer	3.64e-05	0.00014	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TERT—skin cancer	3.63e-05	0.00014	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—NRAS—skin cancer	3.62e-05	0.000139	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—BRAF—skin cancer	3.62e-05	0.000139	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TERT—skin cancer	3.57e-05	0.000137	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—KRAS—skin cancer	3.57e-05	0.000137	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—KRAS—skin cancer	3.51e-05	0.000135	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—KRAS—skin cancer	3.46e-05	0.000133	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—BRAF—skin cancer	3.45e-05	0.000133	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—BRAF—skin cancer	3.4e-05	0.000131	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—KRAS—skin cancer	3.32e-05	0.000128	CbGpPWpGaD
Loxapine—ADRA2A—Hemostasis—TP53—skin cancer	3.31e-05	0.000127	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—NRAS—skin cancer	3.3e-05	0.000127	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TERT—skin cancer	3.29e-05	0.000127	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—NRAS—skin cancer	3.28e-05	0.000126	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—NRAS—skin cancer	3.27e-05	0.000126	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—NRAS—skin cancer	3.26e-05	0.000126	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—TP53—skin cancer	3.24e-05	0.000125	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TERT—skin cancer	3.24e-05	0.000125	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TERT—skin cancer	3.23e-05	0.000124	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TERT—skin cancer	3.22e-05	0.000124	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TERT—skin cancer	3.21e-05	0.000124	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TERT—skin cancer	3.18e-05	0.000122	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—KRAS—skin cancer	3.17e-05	0.000122	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TERT—skin cancer	3.17e-05	0.000122	CbGpPWpGaD
Loxapine—ADRA2A—Hemostasis—HRAS—skin cancer	3.16e-05	0.000122	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—KRAS—skin cancer	3.16e-05	0.000122	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—NRAS—skin cancer	3.16e-05	0.000121	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—NRAS—skin cancer	3.14e-05	0.000121	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—HRAS—skin cancer	3.12e-05	0.00012	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—KRAS—skin cancer	3.12e-05	0.00012	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—HRAS—skin cancer	3.12e-05	0.00012	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—BRAF—skin cancer	3.1e-05	0.000119	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—HRAS—skin cancer	3.1e-05	0.000119	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—HRAS—skin cancer	3.1e-05	0.000119	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—BRAF—skin cancer	3.07e-05	0.000118	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—NRAS—skin cancer	3.05e-05	0.000118	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—HRAS—skin cancer	3.03e-05	0.000117	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—NRAS—skin cancer	3.01e-05	0.000116	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—IL6—skin cancer	2.99e-05	0.000115	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—HRAS—skin cancer	2.98e-05	0.000115	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—IL6—skin cancer	2.98e-05	0.000115	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—BRAF—skin cancer	2.97e-05	0.000114	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—IL6—skin cancer	2.97e-05	0.000114	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—IL6—skin cancer	2.96e-05	0.000114	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—BRAF—skin cancer	2.95e-05	0.000114	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TERT—skin cancer	2.95e-05	0.000113	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—HRAS—skin cancer	2.94e-05	0.000113	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—IL6—skin cancer	2.9e-05	0.000112	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—BRAF—skin cancer	2.87e-05	0.000111	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—IL6—skin cancer	2.86e-05	0.00011	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—KRAS—skin cancer	2.84e-05	0.000109	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—KRAS—skin cancer	2.83e-05	0.000109	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—BRAF—skin cancer	2.83e-05	0.000109	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—TP53—skin cancer	2.82e-05	0.000109	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—HRAS—skin cancer	2.82e-05	0.000108	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—IL6—skin cancer	2.82e-05	0.000108	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—KRAS—skin cancer	2.81e-05	0.000108	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—KRAS—skin cancer	2.81e-05	0.000108	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PTGS2—skin cancer	2.77e-05	0.000107	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—NRAS—skin cancer	2.77e-05	0.000107	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—NRAS—skin cancer	2.73e-05	0.000105	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—NRAS—skin cancer	2.72e-05	0.000105	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—KRAS—skin cancer	2.72e-05	0.000105	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—NRAS—skin cancer	2.71e-05	0.000104	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—NRAS—skin cancer	2.7e-05	0.000104	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—KRAS—skin cancer	2.7e-05	0.000104	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—HRAS—skin cancer	2.7e-05	0.000104	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—IL6—skin cancer	2.7e-05	0.000104	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—HRAS—skin cancer	2.69e-05	0.000103	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—NRAS—skin cancer	2.68e-05	0.000103	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	2.67e-05	0.000103	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—HRAS—skin cancer	2.65e-05	0.000102	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—KRAS—skin cancer	2.63e-05	0.000101	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—BRAF—skin cancer	2.61e-05	0.0001	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—KRAS—skin cancer	2.59e-05	9.96e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—IL6—skin cancer	2.58e-05	9.94e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—IL6—skin cancer	2.57e-05	9.89e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—BRAF—skin cancer	2.56e-05	9.87e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—BRAF—skin cancer	2.56e-05	9.84e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—BRAF—skin cancer	2.55e-05	9.81e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—BRAF—skin cancer	2.54e-05	9.78e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—IL6—skin cancer	2.54e-05	9.76e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—NRAS—skin cancer	2.52e-05	9.7e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—BRAF—skin cancer	2.52e-05	9.69e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—NRAS—skin cancer	2.52e-05	9.68e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—TP53—skin cancer	2.51e-05	9.67e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—BRAF—skin cancer	2.51e-05	9.66e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—NRAS—skin cancer	2.5e-05	9.62e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—TP53—skin cancer	2.5e-05	9.61e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—NRAS—skin cancer	2.48e-05	9.55e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PTGS2—skin cancer	2.46e-05	9.45e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—NRAS—skin cancer	2.45e-05	9.42e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—HRAS—skin cancer	2.41e-05	9.29e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—NRAS—skin cancer	2.41e-05	9.27e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—HRAS—skin cancer	2.4e-05	9.25e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—HRAS—skin cancer	2.39e-05	9.21e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—HRAS—skin cancer	2.39e-05	9.19e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—KRAS—skin cancer	2.39e-05	9.18e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—NRAS—skin cancer	2.38e-05	9.15e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—KRAS—skin cancer	2.35e-05	9.03e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—KRAS—skin cancer	2.34e-05	9.01e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—KRAS—skin cancer	2.33e-05	8.99e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—BRAF—skin cancer	2.33e-05	8.98e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—KRAS—skin cancer	2.33e-05	8.96e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL6—skin cancer	2.31e-05	8.89e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—HRAS—skin cancer	2.31e-05	8.89e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—KRAS—skin cancer	2.3e-05	8.87e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL6—skin cancer	2.3e-05	8.85e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	2.3e-05	8.85e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—HRAS—skin cancer	2.3e-05	8.84e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL6—skin cancer	2.29e-05	8.81e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL6—skin cancer	2.29e-05	8.8e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—NRAS—skin cancer	2.28e-05	8.76e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PTGS2—skin cancer	2.25e-05	8.67e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—HRAS—skin cancer	2.23e-05	8.6e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL6—skin cancer	2.21e-05	8.51e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—HRAS—skin cancer	2.2e-05	8.46e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL6—skin cancer	2.2e-05	8.46e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—NRAS—skin cancer	2.17e-05	8.35e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—KRAS—skin cancer	2.17e-05	8.34e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—KRAS—skin cancer	2.17e-05	8.34e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—KRAS—skin cancer	2.15e-05	8.28e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—NRAS—skin cancer	2.14e-05	8.23e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL6—skin cancer	2.14e-05	8.23e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—KRAS—skin cancer	2.14e-05	8.22e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—KRAS—skin cancer	2.11e-05	8.11e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL6—skin cancer	2.11e-05	8.1e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—KRAS—skin cancer	2.07e-05	7.98e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—KRAS—skin cancer	2.05e-05	7.87e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—HRAS—skin cancer	2.03e-05	7.8e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—HRAS—skin cancer	2e-05	7.68e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—HRAS—skin cancer	1.99e-05	7.66e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—HRAS—skin cancer	1.98e-05	7.64e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—HRAS—skin cancer	1.98e-05	7.61e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—HRAS—skin cancer	1.96e-05	7.54e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—KRAS—skin cancer	1.96e-05	7.54e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	1.95e-05	7.52e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—NRAS—skin cancer	1.95e-05	7.5e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL6—skin cancer	1.94e-05	7.47e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—NRAS—skin cancer	1.93e-05	7.43e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TP53—skin cancer	1.93e-05	7.42e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TP53—skin cancer	1.93e-05	7.41e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TP53—skin cancer	1.91e-05	7.36e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL6—skin cancer	1.91e-05	7.35e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL6—skin cancer	1.91e-05	7.33e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL6—skin cancer	1.9e-05	7.31e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL6—skin cancer	1.89e-05	7.29e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—skin cancer	1.88e-05	7.22e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—skin cancer	1.87e-05	7.21e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—skin cancer	1.87e-05	7.2e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—KRAS—skin cancer	1.87e-05	7.18e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NRAS—skin cancer	1.86e-05	7.18e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NRAS—skin cancer	1.86e-05	7.14e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—HRAS—skin cancer	1.84e-05	7.09e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—skin cancer	1.84e-05	7.09e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—KRAS—skin cancer	1.84e-05	7.09e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—HRAS—skin cancer	1.84e-05	7.09e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—HRAS—skin cancer	1.83e-05	7.04e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—skin cancer	1.82e-05	7e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—HRAS—skin cancer	1.82e-05	6.99e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NRAS—skin cancer	1.8e-05	6.94e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—HRAS—skin cancer	1.79e-05	6.89e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NRAS—skin cancer	1.78e-05	6.83e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—skin cancer	1.76e-05	6.79e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—HRAS—skin cancer	1.76e-05	6.78e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—skin cancer	1.76e-05	6.78e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—skin cancer	1.75e-05	6.74e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—skin cancer	1.74e-05	6.7e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—HRAS—skin cancer	1.74e-05	6.69e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—skin cancer	1.74e-05	6.69e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—skin cancer	1.71e-05	6.6e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—skin cancer	1.69e-05	6.49e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—skin cancer	1.68e-05	6.46e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—HRAS—skin cancer	1.67e-05	6.41e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—skin cancer	1.66e-05	6.4e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—skin cancer	1.66e-05	6.4e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—skin cancer	1.66e-05	6.38e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NRAS—skin cancer	1.64e-05	6.3e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—skin cancer	1.64e-05	6.3e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NRAS—skin cancer	1.61e-05	6.2e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NRAS—skin cancer	1.61e-05	6.19e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—skin cancer	1.61e-05	6.18e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NRAS—skin cancer	1.6e-05	6.17e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NRAS—skin cancer	1.6e-05	6.15e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—skin cancer	1.6e-05	6.15e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—skin cancer	1.59e-05	6.13e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—HRAS—skin cancer	1.59e-05	6.11e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NRAS—skin cancer	1.58e-05	6.09e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NRAS—skin cancer	1.58e-05	6.07e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—HRAS—skin cancer	1.57e-05	6.02e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—skin cancer	1.55e-05	5.98e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—skin cancer	1.53e-05	5.88e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—skin cancer	1.52e-05	5.84e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—skin cancer	1.5e-05	5.77e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—skin cancer	1.49e-05	5.74e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—skin cancer	1.48e-05	5.69e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NRAS—skin cancer	1.47e-05	5.64e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—skin cancer	1.43e-05	5.49e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HRAS—skin cancer	1.43e-05	5.49e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—skin cancer	1.42e-05	5.46e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HRAS—skin cancer	1.41e-05	5.44e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—skin cancer	1.41e-05	5.42e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—skin cancer	1.39e-05	5.34e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—skin cancer	1.38e-05	5.32e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—skin cancer	1.38e-05	5.31e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—skin cancer	1.38e-05	5.31e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—skin cancer	1.37e-05	5.29e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—skin cancer	1.37e-05	5.25e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HRAS—skin cancer	1.36e-05	5.25e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—skin cancer	1.36e-05	5.24e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—skin cancer	1.36e-05	5.23e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—skin cancer	1.36e-05	5.23e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HRAS—skin cancer	1.36e-05	5.22e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—skin cancer	1.35e-05	5.21e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HRAS—skin cancer	1.32e-05	5.08e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—skin cancer	1.31e-05	5.03e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HRAS—skin cancer	1.3e-05	5e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—skin cancer	1.3e-05	5e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—skin cancer	1.26e-05	4.86e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—skin cancer	1.26e-05	4.85e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—skin cancer	1.25e-05	4.82e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—skin cancer	1.24e-05	4.79e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—skin cancer	1.23e-05	4.74e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—skin cancer	1.23e-05	4.73e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—skin cancer	1.23e-05	4.72e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—skin cancer	1.22e-05	4.7e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—skin cancer	1.21e-05	4.66e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—skin cancer	1.21e-05	4.64e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HRAS—skin cancer	1.2e-05	4.61e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HRAS—skin cancer	1.18e-05	4.54e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HRAS—skin cancer	1.18e-05	4.53e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HRAS—skin cancer	1.17e-05	4.51e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HRAS—skin cancer	1.17e-05	4.5e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HRAS—skin cancer	1.16e-05	4.45e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HRAS—skin cancer	1.15e-05	4.44e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—skin cancer	1.15e-05	4.41e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—skin cancer	1.13e-05	4.34e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—skin cancer	1.13e-05	4.33e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—skin cancer	1.12e-05	4.32e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—skin cancer	1.12e-05	4.31e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—skin cancer	1.12e-05	4.3e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—skin cancer	1.11e-05	4.26e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—skin cancer	1.1e-05	4.25e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HRAS—skin cancer	1.07e-05	4.13e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—skin cancer	1.03e-05	3.95e-05	CbGpPWpGaD
